Immune check‐point inhibitor myocarditis: a call for standardized histopathologic criteria

2021 ◽  
Author(s):  
Stefania Rizzo ◽  
Monica De Gaspari ◽  
Cristina Basso
Keyword(s):  
Check Point ◽  
Immune Check Point Inhibitor

scholarly journals PTU-006 Incidence of immune check point inhibitor induced diarrhoea/colitis- experience from a multi-centre cohort

2018 ◽  
Author(s):  
Lavinia Spain ◽  
Amit Samani ◽  
Hajir Ibraheim ◽  
Lewis Au ◽  
Zayd Tippu ◽  
...  
Keyword(s):  
Check Point ◽  
Immune Check Point Inhibitor

Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review

Lung Cancer ◽  
2019 ◽  
Vol 135 ◽  
pp. 29-32 ◽  
Author(s):  
Thomopoulou Konstantina ◽  
Rounis Konstantinos ◽  
Koutsopoulos Anastasios ◽  
Mala Anastasia ◽  
Lagoudaki Eleni ◽  
...  
Keyword(s):  
Literature Review ◽  
Adverse Events ◽  
Check Point ◽  
Immune Check Point Inhibitor ◽  
Fatal Adverse Events

Roles of an immune-check point inhibitor (nivolumab) in heavily pretreated and platinum-resistant gynecologic cancers.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e17562-e17562
Author(s):  
Yoshihiro Kikuchi ◽  
Hiroko Kouta ◽  
Takayoshi Asakawa ◽  
Miyuki Horikoshi ◽  
Tomoyuki Yoshikawa ◽  
...  
Keyword(s):  
Check Point ◽  
Gynecologic Cancers ◽  
Platinum Resistant ◽  
Heavily Pretreated ◽  
Immune Check Point Inhibitor

Cardiovascular complications of immune checkpoint inhibitor therapy.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 2568-2568 ◽  
Author(s):  
Samip R. Master ◽  
Arelis Robinson ◽  
Glenn Morris Mills ◽  
Richard P Mansour
Keyword(s):  
Atrial Fibrillation ◽  
Adverse Effects ◽  
Cardiac Failure ◽  
Checkpoint Inhibitors ◽  
Cardiovascular Complications ◽  
Cardiac Complications ◽  
Check Point ◽  
Pericardial Disease ◽  
Immune Check Point Inhibitor ◽  
Artery Disease

2568 Background: Cardiac toxicity has largely been underestimated toxicity of checkpoint inhibitors. There have been several cases of myocarditis and fatal heart failure reported in patients treated with checkpoint inhibitors. We did a retrospective analysis of data of adverse effects of drugs that has been made available to public by the FDA. Methods: The FDA has made the data on adverse effects of various treatments available to general public through the FDA Adverse Events Reports System (FAERS) public dashboard. We investigated the cardiac toxicities of various immune check point inhibitor therapies available at FDERS for the years 2017-2018. Results: The reviewed the reported side effects of pembrolizumab, nivolumab, atezolizumab, avelumab, durvalumab and ipilimumab from FDA data. A total of 36,848 toxicities from immunotherapies were reported. Out of that, 2316(6.2 %) were cardio toxicities and 816 were fatal. The most common cardiac complications were as follows: myocarditis (15%), atrial fibrillation (13%), pericardial disease including pericardial effusion (13%), cardiac failure (17%) and coronary artery disease (19%). Approximately 50%, 43%, 40% 22% and 15 % of cases with myocarditis, ischemic heart disease, cardiac failure, atrial fibrillation and pericardia disease were fatal. Conclusions: Out of the reported cases of adverse reaction to check point inhibitor, 6.2% were cardio toxicities. 35% of cardio toxicities were fatal. Half of the cases who developed myocarditis died. There was no statistical difference in rate of cardiotoxicities caused by PD1, PDL1 or CTLA 4 inhibitors.

scholarly journals Molecular Characterization of the Clinical and Tumor Immune Microenvironment Signature of 5-methylcytosine-Related Regulators in non-small Cell Lung Cancer

2021 ◽  
Vol 9 ◽  
Author(s):  
Taisheng Liu ◽  
Liyi Guo ◽  
Guihong Liu ◽  
Xiaoshan Hu ◽  
Xiaoning Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tumor Microenvironment ◽  
Immune Cell ◽  
Cell Infiltration ◽  
Immune Cell Infiltration ◽  
Check Point ◽  
Clinical Prognosis ◽  
Tumor Mutation Burden ◽  
Mutation Burden ◽  
Immune Check Point Inhibitor

Background: DNA methylation is an important epigenetic modification, among which 5-methylcytosine methylation (5mC) is generally associated with tumorigenesis. Nonetheless, the potential roles of 5mC regulators in the tumor microenvironment (TME) remain unclear.Methods: The 5mC modification patterns of 1,374 lung adenocarcinoma samples were analyzed systematically. The correlation between the 5mC modification and tumor microenvironment cell infiltration was further assessed. The 5mCscore was developed to evaluate tumor mutation burden, immune check-point inhibitor response, and the clinical prognosis of individual tumors.Results: Three 5mC modification patterns were established based on the clinical characteristics of 21 5mC regulators. According to the differential expression of 5mC regulators, three distinct 5mC gene cluster were also identified, which showed distinct TME immune cell infiltration patterns and clinical prognoses. The 5mCscore was constructed to evaluate the tumor mutation burden, immune check-point inhibitor response, and prognosis characteristics. We found that patients with a low 5mCscore had significant immune cell infiltration and increased clinical benefit.Conclusion: This study indicated that the 5mC modification is involved in regulating TME infiltration remodeling. Targeting 5mC modification regulators might be a novel strategy to treat lung cancer.

scholarly journals Immune Check Point Inhibitor–Associated Glomerulonephritis

2019 ◽  
Vol 4 (2) ◽  
pp. 355-359 ◽  
Author(s):  
Tarek Ashour ◽  
Georges Nakhoul ◽  
Pradnya Patil ◽  
Pauline Funchain ◽  
Leal Herlitz
Keyword(s):  
Check Point ◽  
Immune Check Point Inhibitor
Sign in / Sign up

Export Citation Format

Share Document